Document Detail


Ultrasound evaluation of clobetasol propionate 0.05% foam application in psoriatic and healthy skin: a pilot study.
MedLine Citation:
PMID:  19891687     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The aim of the present study was to evaluate through ultrasound imaging the response to treatment of twice and once daily application of clobetasol propionate 0.05% foam on psoriatic skin as well as the atrophogenic potential of once daily application of the foam on healthy skin. The study included a total of 40 participants, 30 affected by Psoriasis vulgaris and 10 healthy volunteers. Patients with psoriasis were branched in two groups of 15 subjects: in the first group, clobetasol propionate 0.05% foam was applied twice daily for up to 2 weeks on targeted plaques, in the second group, it was applied once daily for up to 4 weeks. Ten healthy adult volunteers were instructed to apply the foam to a 4 x 4 cm area on the volar aspect of the forearm once daily for 4 weeks. Ultrasound evaluation was performed in all treated areas using a 20-MHz B-mode high-resolution system (EasyScan Echo), Business Enterprise, Trapani, Italy). At the end of the study, ultrasound showed a reduction of psoriatic skin thickness, with values equal to those of adjacent healthy skin, in all treated plaques. No differences in treatment efficacy between the two groups of patients with psoriasis were observed. As regards the healthy group, no ultrasound variations in skin thickness were observed at the end of the study. Ultrasound imaging, allowing an objective and reproducible measurement of skin thickness, is a useful technique for a noninvasive evaluation both of the efficacy of psoriasis treatment and of the potential side effects of topical corticosteroids.
Authors:
Francesco Lacarrubba; Beatrice Nardone; Maria Letizia Musumeci; Giuseppe Micali
Related Documents :
8854287 - The effect of silicol gel compared with placebo on papulopustular acne and sebum produc...
10228627 - Proliferation is the main epidermal target in the treatment of psoriatic plaques with o...
14996377 - Calcipotriol and puva as treatment for vitiligo.
18359127 - Intermittent therapy for flare prevention and long-term disease control in stabilized a...
24741387 - The duration of negative pressure wound therapy can be reduced using the heartshield de...
9591987 - Management of clubfoot deformity in amyoplasia.
Publication Detail:
Type:  Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Dermatologic therapy     Volume:  22 Suppl 1     ISSN:  1529-8019     ISO Abbreviation:  Dermatol Ther     Publication Date:  2009 Nov 
Date Detail:
Created Date:  2009-11-06     Completed Date:  2010-02-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9700070     Medline TA:  Dermatol Ther     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  S19-21     Citation Subset:  IM    
Affiliation:
Dermatology Clinic, University of Catania, Catania, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Topical
Adult
Aged
Anti-Inflammatory Agents / administration & dosage*
Clobetasol / administration & dosage*
Female
Humans
Male
Middle Aged
Pilot Projects
Psoriasis / drug therapy*,  ultrasonography*
Skin / drug effects,  ultrasonography
Treatment Outcome
Young Adult
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 25122-41-2/Clobetasol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab.
Next Document:  An overview of delayed pressure urticaria with special emphasis on pathogenesis and treatment.